Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22361798 | 1.00 | DRD2 (0.58) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL22361799 | 1.00 | DRD2 (0.58) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL29548720 | 1.00 | DRD2 (0.58) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL4662846 | 1.00 | DRD2 (0.58) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL28881630 | 0.98 | DRD2 (0.59) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL2228867 | 0.89 | DRD2 (0.62) | DRD2DRD1DRD3LMNAMAPT | |
| SCHEMBL2469614 | 0.86 | LMNA (0.68) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL6433586 | 0.86 | LMNA (0.68) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL11216088 | 0.86 | LMNA (0.68) | DRD2DRD1DRD3CNR2LMNA | |
| SCHEMBL536375 | 0.86 | LMNA (0.68) | DRD2DRD1DRD3CNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414977-B2 | Method of administering seaberry and saw palmetto extracts to inhibit 5α-reductase activity | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250268972-A1 | 5a-REDUCTASE INHIBITOR | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2025-08-28 | — | — | US | disclosed |
| WO-2025110244-A1 | NOVEL COMPOUND AND USE THEREOF | オリザ油化株式会社 | 2025-05-30 | — | — | WO | disclosed |
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12065512-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| US-20230190854-A1 | METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20220370539-A1 | 5a-REDUCTASE INHIBITOR | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2022-11-24 | — | — | US | disclosed |
| US-11478495-B2 | AMPK activating agent | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| EP-4014987-A2 | CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE | Igisu Co., Ltd. (JP) | 2022-06-22 | — | — | EP | disclosed |
| EP-2765145-B1 | SILYLATED POLYBUTADIENE | NIPPON SODA CO (JP) | 2022-03-02 | — | — | EP | disclosed |
| US-20070154575-A1 | Anti-inflammatory agent | ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070141000-A1 | STABILIZED ASCORBIC ACID DERIVATIVE | SHOWA DENKO K.K. | 2007-06-21 | — | — | US | disclosed |
| US-7232857-B2 | Radiation hardenable adhesive composition containing dispersed natural rubber fine particles | TOPPAN FORMS CO., LTD. (JP) | 2007-06-19 | — | — | US | disclosed |
| US-7223775-B2 | Stabilized ascorbic acid derivatives | SHOWA DENKO K.K. (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-1674106-A1 | DIETETIC COMPOSITION | Oryza Oil & Fat Chemical Co., Ltd (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-20060100177-A1 | Stabilized ascorbic acid derivatives | SHOWA DENKO K.K. (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1496889-B1 | STABILIZED ASCORBIC ACID DERIVATIVES | SHOWA DENKO KK (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20050080181-A1 | Radiation hardenable adhesive composition containing dispersed natural rubber fine particles | TOPPAN FORMS CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1496889-A1 | STABILIZED ASCORBIC ACID DERIVATIVES | Showa Denko K.K. (JP) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086384-A1 | STABILIZED ASCORBIC ACID DERIVATIVES | SHOWA DENKO K. K. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100177-A1 | Stabilized ascorbic acid derivatives | RBP1, SOD1, PROC | DRD2 2148/4885DRD1 1083/4885DRD3 2362/4885 |
| US-20230190854-A1 | METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT | PYGM, MUSK, GCK | DRD2 2765/4885DRD1 2557/4885DRD3 2780/4885 |
| US-20070154575-A1 | Anti-inflammatory agent | TNF, IL18, CD14 | DRD2 2094/4885DRD1 1584/4885DRD3 1457/4885 |
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | DRD2 3809/4885DRD1 2929/4885DRD3 2894/4885 |
| US-11478495-B2 | AMPK activating agent | PRKAG2, PRKAG1, PRKAG3 | DRD2 2845/4885DRD1 2861/4885DRD3 3896/4885 |
| US-12065512-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | DRD2 3809/4885DRD1 2929/4885DRD3 2894/4885 |
| US-20070141000-A1 | STABILIZED ASCORBIC ACID DERIVATIVE | SOD1, PROC, RBP1 | DRD2 2137/4885DRD1 1202/4885DRD3 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.